N6-methyladenosine methylation in kidney injury

Clin Epigenetics. 2023 Oct 21;15(1):170. doi: 10.1186/s13148-023-01586-7.

Abstract

Multiple mechanisms are involved in kidney damage, among which the role of epigenetic modifications in the occurrence and development of kidney diseases is constantly being revealed. However, N6-methyladenosine (M6A), a well-known post-transcriptional modification, has been regarded as the most prevalent epigenetic modifications in higher eukaryotic, which is involved in various biological processes of cells such as maintaining the stability of mRNA. The role of M6A modification in the mechanism of kidney damage has attracted widespread attention. In this review, we mainly summarize the role of M6A modification in the progression of kidney diseases from the following aspects: the regulatory pattern of N6-methyladenosine, the critical roles of N6-methyladenosine in chronic kidney disease, acute kidney injury and renal cell carcinoma, and then reveal its potential significance in the diagnosis and treatment of various kidney diseases. A better understanding of this field will be helpful for future research and clinical treatment of kidney diseases.

Keywords: Epigenetic modification; Kidney injury; M6A; The regulation of M6A.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • DNA Methylation*
  • Humans
  • Kidney / metabolism
  • Kidney Diseases* / genetics
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism

Substances

  • RNA, Messenger